UNBELIEVABLE: Incy - The Untold Story

How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?

Incyte is gaining momentum, recently outperforming the biotech sector and keeping analysts broadly positive on the stock.

Barchart · Sep 23

Incyte Stock: Is Wall Street Bullish or Bearish?

While Incyte has outperformed the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart · Aug 18

What to Expect From Incyte's Q2 2026 Earnings Report

Incyte is scheduled to release its second-quarter results later this month, with analysts projecting a double-digit increase in its bottom line figure.

Barchart · Jul 16

Here's What to Expect From Incyte’s Next Earnings Report

Incyte is scheduled to release its first-quarter results soon, with analysts projecting double-digit surge in its bottom line figure.

Barchart · Apr 15

Is Incyte Stock Outperforming the Dow?

Incyte has outperformed the Dow over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart · Mar 20

Do Wall Street Analysts Like Incyte Corporation Stock?

Wall Street is keeping a confident yet pragmatic stance on Incyte Corporation, supported by steady growth and a promising pipeline.

Barchart · Feb 12

Stocks Climb on Fed Rate Cut Hopes

The S&P 500 Index ($SPX ) (SPY ) today is up +0.18%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.15%. March E-mini S&P futures (ESH26 ) are up +0.17%, and March E-mini Nasdaq futures...

Barchart · Feb 10

Earnings Preview: What To Expect From Incyte's Report

Incyte is scheduled to release its fourth-quarter results soon, with analysts projecting double-digit surge in its bottom line figure.

Barchart · Jan 13

Is Incyte Stock Outperforming the Nasdaq?

Despite Incyte’s outperformance relative to the Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart · Dec 15, 2025

Incyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer

Incyte Corporation (NASDAQ:INCY) on Sunday revealed new clinical data from two Phase 1 studies of INCA033989 for mutCALR-expressing myeloproliferative neoplasms (MPNs) at the 2025 American Society of Hematology (ASH) Annual Meeting.

Benzinga · Dec 8, 2025